
浏览全部资源
扫码关注微信
1.400038 重庆,陆军军医大学(第三军医大学)军事预防医学系军队流行病学教研室
2.400037 重庆,陆军军医大学(第三军医大学)第二附属医院呼吸内科研究所,全军呼吸病研究重点实验室
[李亚斐, E-mail: liyafei2008@hotmail.comLI Yafei, E-mail: liyafei2008@hotmail.com
收稿:2023-09-01,
修回:2023-12-28,
纸质出版:2024-06-15
移动端阅览
万围萍, 谢薇佳, 夏婷婷, 等. 长链非编码RNA SFTA1P在肺鳞状细胞癌中的表达及其对肺鳞状细胞癌细胞生物学功能的影响[J]. 陆军军医大学学报, 2024,46(11):1226-1234.
Weiping WAN, Weijia XIE, Tingting XIA, et al. Expression of long non-coding RNA SFTA1P and its effect on biological functions in lung squamous cell carcinoma[J]. Journal of Army Medical University, 2024, 46(11): 1226-1234.
万围萍, 谢薇佳, 夏婷婷, 等. 长链非编码RNA SFTA1P在肺鳞状细胞癌中的表达及其对肺鳞状细胞癌细胞生物学功能的影响[J]. 陆军军医大学学报, 2024,46(11):1226-1234. DOI: 10.16016/j.2097-0927.202309005.
Weiping WAN, Weijia XIE, Tingting XIA, et al. Expression of long non-coding RNA SFTA1P and its effect on biological functions in lung squamous cell carcinoma[J]. Journal of Army Medical University, 2024, 46(11): 1226-1234. DOI: 10.16016/j.2097-0927.202309005.
目的
2
探究长链非编码RNA表面活性剂相关1假基因(surfactant associated 1 pseudogene,SFTA1P)在肺鳞状细胞癌(简称肺鳞癌)中的表达水平及其对肺鳞癌细胞生物学功能的影响。
方法
2
提取癌症基因组图谱(the cancer genome atlas
TCGA)数据库数据,分析SFTA1P在肺鳞癌组织及正常肺组织中的表达差异;qRT-PCR检测SFTA1P在人正常肺上皮细胞系(BEAS-2B)和肺鳞癌细胞系(H520和SK-MES-1)中的表达;通过转染SFTA1P过表达质粒及SFTA1P小干扰RNA分别构建SFTA1P过表达及干扰细胞模型;通过CCK-8及Transwell实验检测SFTA1P对肺鳞癌细胞生物学功能的影响;通过差异分析、相关性分析和功能富集分析探讨SFTA1P影响肺鳞癌细胞生物学功能的潜在机制。
结果
2
TCGA数据库肺鳞癌样本分析结果显示,SFTA1P在肺鳞癌组织中表达较正常肺组织低(
P
<
0.05);SFTA1P在肺鳞癌细胞中表达也较人正常肺上皮细胞低(
P
<
0.05);在肺鳞癌细胞系中,相比于H520细胞株,SFTA1P在SK-MES-1细胞株中相对低表达(
P
<
0.05);细胞功能实验结果发现,过表达SFTA1P可抑制肺鳞癌细胞增殖、迁移及侵袭(
P
<
0.05),敲低SFTA1P可增强肺鳞癌细胞增殖、迁移及侵袭(
P
<
0.05);差异分析、相关性分析和功能富集分析结果表明,SFTA1P在肺鳞癌中可能抑制MYC、G2m检查点和E2f等信号通路。
结论
2
SFTA1P在肺鳞癌中具有抑癌功能,其可能通过抑制MYC、G2m检查点和E2f等信号通路影响肺鳞癌细胞的生物学功能。
Objective
2
To investigate the expression of long non-coding RNA (lncRNA)
surfactant associated 1 pseudogene (SFTA1P) in lung squamous carcinoma and its effect on the biological functions of SFTA1P in lung squamous carcinoma cell lines.
Methods
2
Based on the cancer genome atlas (TCGA) database
the differential expression of SFTA1P in tumor and normal tissues were compared in patients diagnosed with lung squamous cell carcinoma. Then
the expression of SFTA1P was detected in human normal lung epithelial cell line BEAS-2B and lung squamous cell lines SK-MES-1 and H520 with real-time quantitative polymerase chain reaction (RT-qPCR). SK-MES-1 and H520 cells with overexpression and/or knockdown of SFTA1P were constructed by transfecting the overexpression plasmids (pcDNA3.1-SFTA1P) and small interfering RNAs (si-SFTA1P-1 and si-SFTA1P-2). CCK-8 assay and Transwell assay were used to investigate the effect of SFTA1P on biological functions in lung squamous carcinoma cells. Differential gene expression analysis
correlation analysis and functional enrichment analysis were employed to explore the potential mechanism that SFTA1P may affect biological functions of lung squamous cells.
Results
2
Analysis of TCGA showed that the expression of SFTA1P was significantly lower in lung squamous cell carcinoma tissue than adjacent normal tissue (
P
<
0.05). RT-PCR results showed that the expression of SFTA1P was obviously lower in lung squamous carcinoma cells than the human normal lung epithelial cells (
P
<
0.05). And the expression level of SFTA1P was relatively lower in the SK-MES-1 cells than the H520 cells (
P
<
0.05). Overexpression of SFTA1P suppressed the proliferation
migration and invasion of lung squamous carcinoma cells (
P
<
0.05)
while its knockdown promoted these abilities (
P
<
0.05). Differential gene expression analysis
correlation analysis and functional enrichment analysis indicated that SFTA1P may inhibit MYC
G2m checkpoints and E2f signaling pathways in lung squa
mous cell carcinoma.
Conclusion
2
SFTA1P shows anti-cancer function in lung squamous cell carcinoma
and it may affect the biological functions of lung squamous cell carcinoma cells through down-regulating MYC
G2m checkpoints and E2f signaling pathways.
LEITER A, VELUSWAMY R R, WISNIVESKY J P. The global burden of lung cancer: current status and future trends[J]. Nat Rev Clin Oncol, 2023, 20(9): 624-639. DOI: 10.1038/s41571-023-00798-3.
SUNG H, FERLAY J, SIEGEL R L, et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
DE MARTEL C, GEORGES D, BRAY F, et al . Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J ] . Lancet Glob Health, 2020, 8(2): e180-e190. DOI: 10.1016/S2214-109X(19)30488-7.
SCHABATH M B, COTE M L. Cancer progress and priorities: lung cancer[J]. Cancer Epidemiol Biomarkers Pr, 2019, 28(10): 1563-1579. DOI: 10.1158/1055-9965.EPI-19-0221.
GBD Respiratory Tract Cancers Collaborators. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Respir Med, 2021, 9(9): 1030-1049. DOI: 10.1016/S2213-2600(21)00164-8.
ZHOU M G, WANG H D, ZENG X Y, et al . Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J ] . Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
BRAICU C, ZIMTA A A, HARANGUS A, et al . The function of non-coding RNAs in lung cancer tumorigenesis[J ] . Cancers, 2019, 11(5): 605. DOI: 10.3390/cancers11050605.
TAN Y T, LIN J F, LI T, et al . LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer[J ] . Cancer Commun, 2021, 41(2): 109-120. DOI: 10.1002/cac2.12108.
DAI J L, QU T Y, YIN D D, et al . LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer[J ] . Cell Death Dis, 2023, 14(5): 312. DOI: 10.1038/s41419-023-05840-x.
DONG H L, ZENG L L, CHEN W W, et al . N6-methyladenine-mediated aberrant activation of the lncRNA SOX2OT-GLI1 loop promotes non-small-cell lung cancer stemness[J ] . Cell Death Discov, 2023, 9(1): 149. DOI: 10.1038/s41420-023-01442-w.
ZHAN T, CHENG X T, ZHU Q X, et al . LncRNA LOC105369504 inhibits tumor proliferation and metastasis in colorectal cancer by regulating PSPC1[J ] . Cell Death Discov, 2023, 9(1): 89. DOI: 10.1038/s41420-023-01384-3.
LI Z J, CHENG J, SONG Y, et al . LncRNA SNHG5 upregulation induced by YY1 contributes to angiogenesis via miR-26b/CTGF/VEGFA axis in acute myelogenous leukemia[J ] . Lab Invest, 2021, 101(3): 341-352. DOI: 10.1038/s41374-020-00519-9..
WANG G B, LI H, HOU Y. LncRNA MAGI2-AS3 inhibits tumor progression and angiogenesis by regulating ACY1 via interacting with transcription factor HEY1 in clear cell renal cell carcinoma[J ] . Cancer Gene Ther, 2022, 29(5): 585-596. DOI: 10.1038/s41417-021-00339-z.
SHI C J, XUE Z H, ZENG W Q, et al . LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling[J ] . Cancer Gene Ther, 2023, 30(6): 855-865. DOI: 10.1038/s41417-023-00595-1.
SINGH D, ASSARAF Y G, GACCHE R N. Long non-coding RNA mediated drug resistance in breast cancer[J]. Drug Resist Updat, 2022, 63: 100851. DOI: 10.1016/j.drup.2022.100851.
MA H W, MA T S, CHEN M, et al . The pseudogene-derived long non-coding RNA SFTA1P suppresses cell proliferation, migration, and invasion in gastric cancer[J ] . Biosci Rep, 2018, 38(2): BSR20171193. DOI: 10.1042/BSR20171193.
DU D D, SHEN X, ZHANG Y Q, et al . Expression of long non-coding RNA SFTA1P and its function in non-small cell lung cancer[J ] . Pathol Res Pract, 2020, 216(9): 153049. DOI: 10.1016/j.prp.2020.153049.
LUO A R, LAN X X, QIU Q Z, et al . LncRNA SFTA1P promotes cervical cancer progression by interaction with PTBP1 to facilitate TPM4 mRNA degradation[J ] . Cell Death Dis, 2022, 13(11): 936. DOI: 10.1038/s41419-022-05359-7.
陈梦雷, 袁帅, 周玫余, 等. 长链非编码RNA SFTA1P在肺腺癌中的表达及预后预测研究[J]. 第三军医大学学报, 2020, 42(21): 2075-2080, 2115. DOI: 10.16016/j.1000-5404.202005271.
CHEN M L, YUAN S, ZHOU M Y, et al . Expression of long non-coding RNA SFTA1P in lung adenocarcinoma and its predictive value for prognosis[J ] . J Third Mil Med Univ, 2020, 42(21): 2075-2080, 2115. DOI: 10.16016/j.1000-5404.202005271.
YE P, LV X Y, AIZEMAITI R, et al . H3K27ac-activated LINC00519 promotes lung squamous cell carcinoma progression by targeting miR-450b-5p/miR-515-5p/YAP1 axis[J ] . Cell Prolif, 2020, 53(5): e12797. DOI: 10.1111/cpr.12797.
MA J, QI G B, LI L. LncRNA NNT-AS1 promotes lung squamous cell carcinoma progression by regulating the miR-22/FOXM1 axis[J]. Cell Mol Biol Lett, 2020, 25: 34. DOI: 10.1186/s11658-020-00227-8.
HU Z Y, LIU Y X, TANG J, et al . LncRNA HHIP-AS1 suppresses lung squamous cell carcinoma by stabilizing HHIP mRNA[J ] . Life Sci, 2023, 321: 121578. DOI: 10.1016/j.lfs.2023.121578.
ZHU H Y, LIU Q Y, YANG X B, et al . LncRNA LINC00649 recruits TAF15 and enhances MAPK6 expression to promote the development of lung squamous cell carcinoma via activating MAPK signaling pathway[J ] . Cancer Gene Ther, 2022, 29(8/9): 1285-1295. DOI: 10.1038/s41417-021-00410-9..
ZHAO X, WANG J Z, ZHU R, et al . DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis[J ] . Sci Rep, 2021, 11(1): 21014. DOI: 10.1038/s41598-021-99555-8.
HUANG G H, YANG Y M, LV M X, et al . Novel lncRNA SFTA1P promotes tumor growth by down-regulating miR-4766-5p via PI3K/AKT/mTOR signaling pathway in hepatocellular carcinoma[J ] . Onco Targets Ther, 2020, 13: 9759-9770. DOI: 10.2147/OTT.S248660.
ZHANG H, XIONG Y Q, XIA R, et al . The pseudogene-derived long noncoding RNA SFTA1P is down-regulated and suppresses cell migration and invasion in lung adenocarcinoma[J ] . Tumour Biol, 2017, 39(2): 1010428317691418. DOI: 10.1177/1010428317691418.
ZHANG W Q, BAI M C, LIU K Q, et al . LncRNA surfactant associated 1 activates large tumor suppressor kinase 1/Yes-associated protein pathway via modulating hypoxic exosome-delivered miR-4766-5p to inhibit lung adenocarcinoma metastasis[J ] . Int J Biochem Cell Biol, 2022, 153: 106317. DOI: 10.1016/j.biocel.2022.106317..
ZHU B W, FINCH-EDMONDSON M, LEONG K W, et al . LncRNA SFTA1P mediates positive feedback regulation of the Hippo-YAP/TAZ signaling pathway in non-small cell lung cancer[J ] . Cell Death Discov, 2021, 7(1): 369. DOI: 10.1038/s41420-021-00761-0.
LI L, YIN J Y, HE F Z, et al . Long noncoding RNA SFTA 1 P pr omoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma[J ] . Oncotarget, 2017, 8(57): 97476-97489. DOI: 10.18632/oncotarget.22138..
DHANASEKARAN R, DEUTZMANN A, MAHAUAD-FERNANDEZ W D, et al . The MYC oncogene-the grand orchestrator of cancer growth and immune evasion[J ] . Nat Rev Clin Oncol, 2022, 19(1): 23-36. DOI: 10.1038/s41571-021-00549-2.
ZHU Q Q, ZHANG C G, QU T Y, et al . MNX1-AS1 promotes phase separation of IGF2BP1 to drive c-myc-mediated cell-cycle progression and proliferation in lung cancer[J ] . Cancer Res, 2022, 82(23): 4340-4358. DOI: 10.1158/0008-5472.CAN-22-1289.
ZHANG L W, HE M, ZHU W J, et al . Identification of a panel of mitotic spindle-related genes as a signature predicting survival in lung adenocarcinoma[J ] . J Cell Physiol, 2020, 235(5): 4361-4375. DOI: 10.1002/jcp.29312.
MALANEY P, PALUMBO E, SEMIDEY-HURTADO J, et al . PTEN physically interacts with and regulates E2F1-mediated transcription in lung cancer[J ] . Cell Cycle, 2018, 17(8): 947-962. DOI: 10.1080/15384101.2017.1388970.
YAO Y, NG J F, PARK W D, et al . CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma[J ] . Blood, 2023, 141(23): 2841-2852. DOI: 10.1182/blood.2022018885.
0
浏览量
98
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621